Fig. 6: CD126-targeted CAR-T cells demonstrated potent antitumor activity in murine models of multiple myeloma and prostate cancer.
From: Preclinical development of CD126 CAR-T cells with broad antitumor activity
a Tumor-infiltrating human T cells were quantified by anti-human CD3 antibody using flow cytometry in RPMI tumors explanted from mice that either received mock T cells (n = 8) or CAR-T cells (n = 10). b Tumor-infiltrating human T cells was quantified by anti-human CD3 antibody using flow cytometry of DU145-explanted tumors from mice that either received mock T cells (n = 5) or CAR-T cells (n = 4). c Representative images from five mice are shown from DU145 xenograft model. Mann–Whitney U non-parametric test. *P < 0.05 and ****P < 0.0001.
